Sagimet Biosciences INC. (SGMT) — 10-Q Filings

10-Q Filings (6)

• Sagimet's Cash Dwindles Amid Rising R&D, MASH & Acne Trials Advance — Nov 13, 2025 Risk: high
  Sagimet Biosciences Inc. reported a net loss of $12.908 million for the three months ended September 30, 2025, an improvement from a net loss of $14.619 million
• Sagimet's Losses Double Amid R&D Surge, Cash Dwindles — Aug 13, 2025 Risk: high
  Sagimet Biosciences Inc. reported a significant increase in net loss for the six months ended June 30, 2025, reaching $28.56 million, up from $14.75 million in
• Sagimet Biosciences Files Q1 2025 10-Q — May 8, 2025 Risk: low
  Sagimet Biosciences Inc. filed its 10-Q for the period ending March 31, 2025. The company, formerly known as 3-V Biosciences, Inc., reported financial data incl
• Sagimet Biosciences Q3 2024 Update: Financial Snapshot — Nov 14, 2024 Risk: medium
  Sagimet Biosciences Inc. filed its 10-Q for the period ending September 30, 2024. The company reported cash and cash equivalents of $30.7 million. Key financia
• Sagimet Biosciences Q2 2024: Net Loss of $21.4M — Aug 14, 2024 Risk: medium
  Sagimet Biosciences Inc. filed its 10-Q for the period ending June 30, 2024. The company reported total assets of $30.4 million and total liabilities of $1.5 mi
• Sagimet Biosciences Inc. Files 10-Q for Period Ending March 31, 2024 — May 15, 2024 Risk: low
  Sagimet Biosciences Inc. (SGMT) filed a Quarterly Report (10-Q) with the SEC on May 15, 2024. Sagimet Biosciences Inc. filed a 10-Q for the period ending March

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX